Kristy Ainslie, Ph.D. applies her knowledge base in biomaterials, and immunology to develop new immune-modulatory therapies that treat and prevent infectious, and autoimmune diseases. Her lab aims to design practical and innovative formulations, taking into account the scalable production and applications in developing nations.
Drug Delivery: Faculty and Staff
The Anselmo lab focuses on understanding microbe-material-host tissue interactions to develop: (i) formulations for the improved delivery of therapeutic microbes, (ii) materials-based in vitro culture approaches to enable the co-culture of microbial ecologies alongside mammalian cells, and (iii) targeted approaches for the delivery of therapeutic microbes.
Due to their expansive utility, stem cell-based therapies hold the potential to redefine therapeutic approaches and provide cures for many terminal diseases. In the Hingtgen lab, we seek to harness the potential of stem cells to develop new and better methods for treating terminal cancers, including brain cancer. We use an integrative approach that begins with creating specially designed targeted therapeutic proteins.
The Laboratory of Drug Targeting has been working on liposomes and immunoliposomes for drug delivery. Current activities are focused in the development of nonviral vectors for gene (including siRNA) therapy, and receptor mediated drug and vaccine targeting using self-assembled nanoparticles. The technologies are tested for therapy of cancer and liver diseases in animal models.
Mike Jay, Ph.D., received his B.S. in pharmacy from the State University of New York at Buffalo in 1976 and his Ph.D. in pharmaceutical sciences from the University of Kentucky in 1980. He was an assistant professor of nuclear medicine at the University of Connecticut Health Center from 1980 to 1981 and then returned to the University of Kentucky as an assistant professor of medicinal chemistry in 1981 and rose through the academic ranks. By the end of his twenty-seven years at the University of Kentucky, he was professor of pharmaceutics and professor of radiology.
Alexander “Sasha” Kabanov, Ph.D., Dr.Sci., is the Mescal Swaim Ferguson Distinguished Professor and director of the Center for Nanotechnology in Drug Delivery at the UNC Eshelman School of Pharmacy and codirector of the Carolina Institute for Nanomedicine at the University of North Carolina at Chapel Hill. Prior to joining UNC-Chapel Hill in July 2012, Kabanov served for nearly eighteen years at the University of Nebraska Medical Center where he was the Parke-Davis Professor of Pharmaceutical Sciences and director of the Center for Drug Delivery and Nanomedicine, which he founded in 2004.
Sam Lai, Ph.D., was born in Hong Kong and spent his childhood in both Hong Kong and Vancouver. After completing high school at Phillips Academy, Andover, he attended Cornell University and received his BS in chemical and biomolecular engineering in 2003. He then undertook doctoral studies at Johns Hopkins University, receiving his PhD in chemical and biomolecular engineering in 2007. Following a one-year postdoc, he became a research assistant professor at Johns Hopkins in fall 2008 before joining the UNC Eshelman School of Pharmacy in fall 2010.
Dr. Juliane Nguyen is an Associate Professor in the Division of Pharmacoengineering and Molecular Pharmaceutics. Her translational research program focuses on developing the next generation of safe and effective biotherapeutics for life-threatening diseases such as cancer and myocardial infarction.
In the Schoenfisch Lab, we work at the interface of analytical chemistry, materials science, biomedical engineering, and biology. The types of multi-disciplinary research opportunities that are available include studies of therapeutics to treat various diseases; sensors that function reliably and continuously, real time, to facilitate disease management; microelectrode and microfluidic sensor design and fabrication for clinical, point-of-care, and diagnostic/prognostic applications; and, new macromolecular scaffolds that manipulate biology and physiology.
Dr. Smith received a B.S. in Pharmacy from the University of Illinois, Chicago Medical Center, and then a Ph.D. in Pharmaceutical Chemistry, with an emphasis in pharmacokinetics, in 1985 from the University of California, San Francisco. After postdoctoral studies at the National Institutes of Health in Bethesda, MD, as a National Research Council Fellow, he joined the faculty of the College of Pharmacy at the University of Texas at Austin.
Prior to joining UNC in 2007, Dayton was research faculty at the University of California at Davis. His research interests currently involve applications of ultrasound imaging for assessment of tissue perfusion and monitoring of response to therapy. Other interests include ultrasound-mediated therapeutic approaches.
The Zongchao Han, Ph.D., M.D., laboratory is interested in developing gene therapies for retinal diseases. Han’s lab is particularly interested in understanding the gene expression patterns that are regulated by the cis-regulatory elements. Another interest of the Han laboratory is to produce a multifunctional NP carrier for specific and efficient gene/drug targeting.
Bachelder focuses on the development of biomaterials for the treatment of diseases associated with the immune system, inlcuding using liposomes, acid sensitive polymers, and tissue engineering scaffolds.
The main focus of Batrakova’s research is to develop a CNS delivery system for antioxidants and neuronal growth factors to attenuate neuroinflammation and produce neuroprotection in patients with neurodegenerative disorders, such as Parkinson’s and Alzheimer’s diseases. For this purpose, her group utilizes inflammatory-response cells, macrophages and monocytes that can migrate toward the inflammation site, cross the blood brain barrier, and release the preloaded drugs in the brain.
Sokolsky-Papkov’s current research centers on design of nano-based, sustained release and remote actuated drug delivery systems for treatment and diagnosis of cancer. My research utilizes several platform nanoparticles based technologies (polymeric micelles and nanoparticles, cell derived exosomes and inorganic nanoparticles) and is focused on engineering treatment modalities for two main types of cancer: brain cancer and brain metastases and diagnosis and treatment of post operative residual disease and metastatic spread with emphasis on (1) designing drug loaded nanoparticles which can effectively home to brain cancer in vivo and deliver tumor specific payload to improve treatment efficacy (2) utilize sustained release and nanotechnology approaches to design delivery systems which can improve non invasive diagnosis of primary metastatic spread, treat residual disease and promote post-operative would healing and (3) utilize intrinsic properties of inorganic nanoparticles to design theranostic delivery systems which combine remotely induced drug release and cell apoptosis.